11:38 AM EDT, 05/30/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) on Thursday confirmed the closing of its 9% debenture financing at US$1,000 per convertible note due May 1, 2028 raising C$8.5 million.

Proceeds will be primarily used on its Phase III registration trial (Tigris) for its PMX treatment for endotoxemic septic shock and for general corporate and working capital purpose.

The company's shares were last seen up $0.005 to $0.48 on the Toronto Stock Exchange.

Price: 0.48, Change: +0.01, Percent Change: +1.05